JP2015514421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514421A5 JP2015514421A5 JP2015507006A JP2015507006A JP2015514421A5 JP 2015514421 A5 JP2015514421 A5 JP 2015514421A5 JP 2015507006 A JP2015507006 A JP 2015507006A JP 2015507006 A JP2015507006 A JP 2015507006A JP 2015514421 A5 JP2015514421 A5 JP 2015514421A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- seq
- chain
- class
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625314P | 2012-04-17 | 2012-04-17 | |
| US61/625,314 | 2012-04-17 | ||
| PCT/US2013/032058 WO2013158292A1 (en) | 2012-04-17 | 2013-03-15 | Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019289A Division JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015514421A JP2015514421A (ja) | 2015-05-21 |
| JP2015514421A5 true JP2015514421A5 (https=) | 2016-05-12 |
Family
ID=48045753
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507006A Pending JP2015514421A (ja) | 2012-04-17 | 2013-03-15 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2019019289A Active JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2022132891A Active JP7531925B2 (ja) | 2012-04-17 | 2022-08-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2024118377A Pending JP2024144548A (ja) | 2012-04-17 | 2024-07-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019019289A Active JP7130571B2 (ja) | 2012-04-17 | 2019-02-06 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2022132891A Active JP7531925B2 (ja) | 2012-04-17 | 2022-08-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
| JP2024118377A Pending JP2024144548A (ja) | 2012-04-17 | 2024-07-24 | Ｈｌａクラスｉｉタンパク質の発現能を有するｈｌａクラスｉｉ欠損細胞、ｈｌａクラスｉ欠損細胞、及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20150056225A1 (https=) |
| EP (2) | EP4253409A3 (https=) |
| JP (4) | JP2015514421A (https=) |
| AU (1) | AU2013249820C1 (https=) |
| CA (2) | CA2870571C (https=) |
| DK (1) | DK2838548T5 (https=) |
| ES (1) | ES2959382T3 (https=) |
| FI (1) | FI2838548T3 (https=) |
| HU (1) | HUE063231T2 (https=) |
| PL (1) | PL2838548T3 (https=) |
| PT (1) | PT2838548T (https=) |
| WO (1) | WO2013158292A1 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6681837B2 (ja) * | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| EP3215623A4 (en) * | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| CN116059378A (zh) | 2014-12-10 | 2023-05-05 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
| CN107208055B (zh) * | 2015-01-17 | 2021-06-15 | 浙江大学 | 引起免疫原性反应降低的被修饰细胞 |
| WO2016123100A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN107921148A (zh) | 2015-05-08 | 2018-04-17 | 哈佛学院校长同事会 | 通用供体干细胞和相关方法 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| SG11201803145RA (en) | 2015-11-04 | 2018-05-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| KR20250141836A (ko) | 2015-11-04 | 2025-09-29 | 페이트 세러퓨틱스, 인코포레이티드 | 만능 세포의 유전자 조작 |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| WO2017122130A1 (en) | 2016-01-11 | 2017-07-20 | Novartis Ag | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
| WO2017185169A1 (en) * | 2016-04-27 | 2017-11-02 | University Health Network (Uhn) | Pept1de-hla complexes and methods of producing same |
| JP2020505025A (ja) * | 2017-01-13 | 2020-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫工学的な改変をした多能性細胞 |
| CA3094322A1 (en) * | 2017-03-20 | 2018-09-27 | Washington University | Cells and methods of uses and making the same |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CA3067914A1 (en) | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| EP3684399A1 (en) | 2017-12-29 | 2020-07-29 | Cellectis | Method for improving production of car t cells |
| WO2019129850A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US12331318B2 (en) | 2018-07-13 | 2025-06-17 | Lothar Germeroth | Non-immunogenic engineered tissue and methods of producing and using the same |
| US20210322473A1 (en) * | 2018-07-18 | 2021-10-21 | The General Hospital Corporation | Modified t cells and methods of their use |
| CN110819592A (zh) * | 2018-08-13 | 2020-02-21 | 赛元生物科技(杭州)有限公司 | 一种通用供体干细胞及其制备方法 |
| CN120174005A (zh) | 2019-02-13 | 2025-06-20 | 比姆医疗股份有限公司 | 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞 |
| US12221622B2 (en) | 2019-05-10 | 2025-02-11 | The Regents Of The University Of California | Modified pluripotent cells |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| JP7743980B2 (ja) * | 2020-02-07 | 2025-09-25 | 学校法人順天堂 | ヒトＴ細胞由来ｉＰＳ細胞由来の細胞傷害性Ｔ細胞 |
| EP4149525A4 (en) * | 2020-05-15 | 2024-08-28 | Rxcell Inc. | HYPOIMMUNOGENIC CELLS AND THEIR USES IN IMMUNE RESPONSES |
| BR112023003036A2 (pt) | 2020-08-19 | 2023-04-25 | Astellas Pharma Inc | Região fc modificada de ocorrência não natural humana de igg especificamente ligando-se a receptor de fc modificado de ocorrência não natural |
| EP4200023A4 (en) * | 2020-08-23 | 2024-10-30 | Applied StemCell, Inc. | Hla-f-modified cells and methods |
| CN114350612A (zh) * | 2020-09-28 | 2022-04-15 | 未来智人再生医学研究院(广州)有限公司 | 表达靶向CTLA-4的shRNA/shRNA-miR的多能干细胞或其衍生物 |
| CN114276995A (zh) * | 2020-09-28 | 2022-04-05 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ctla-4阻遏分子的多能干细胞及其衍生物 |
| CN114457030A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达IgE阻断物的多能干细胞或其衍生物及应用 |
| CN114517184A (zh) * | 2020-10-30 | 2022-05-20 | 未来智人再生医学研究院(广州)有限公司 | 一种表达adipsin的多能干细胞或其衍生物及应用 |
| CN114457028A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd38抗体的多能干细胞及其衍生物与应用 |
| CN114525257A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Tim-3阻断物的多能干细胞或其衍生物及应用 |
| CN114457026A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用 |
| CN114457033A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达il-6阻断物的多能干细胞衍生物及其应用 |
| CN114525254A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达fgf-21的多能干细胞或其衍生物及应用 |
| CN114457021A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd47抗体的多能干细胞及其衍生物与应用 |
| CN114457022A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用 |
| CN114457024A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN114645021A (zh) * | 2020-12-21 | 2022-06-21 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用 |
| CN114657131A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达尿酸氧化酶的多能干细胞或其衍生物 |
| CN114657130A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用 |
| CN114717192A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Amyloidβ靶向抑制因子的多能干细胞及其衍生物与应用 |
| CN114717193A (zh) * | 2020-12-22 | 2022-07-08 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向B7-H5的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
| CN114657138A (zh) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达靶向B7-H4的shRNA和/或shRNA-miR的多能干细胞或其衍生物 |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| JPWO2022191216A1 (https=) | 2021-03-09 | 2022-09-15 | ||
| CN117242173A (zh) | 2021-05-03 | 2023-12-15 | 安斯泰来再生医药协会 | 产生成熟角膜内皮细胞的方法 |
| WO2022235869A1 (en) | 2021-05-07 | 2022-11-10 | Astellas Institute For Regenerative Medicine | Methods of generating mature hepatocytes |
| EP4359541A4 (en) * | 2021-06-23 | 2025-04-30 | Editas Medicine, Inc. | Engineered cells for therapy |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| US20260002124A1 (en) | 2022-07-01 | 2026-01-01 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| TW202417614A (zh) | 2022-08-23 | 2024-05-01 | 安斯泰來再生醫藥協會 | 用於治療眼部病症的感光救援細胞（prc）組成物及方法 |
| CN118207165B (zh) * | 2022-12-07 | 2026-03-20 | 士泽生物医药（苏州）有限公司 | 一种表达stc1的通用型细胞及其制备方法 |
| EP4735585A1 (en) | 2023-06-30 | 2026-05-06 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| WO1991010470A1 (en) | 1990-01-08 | 1991-07-25 | Brown University Research Foundation | Devices and methods for enhanced delivery of active factors |
| WO1992009688A1 (en) * | 1990-11-21 | 1992-06-11 | Massachusetts Institute Of Technology | MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION |
| US5837234A (en) | 1995-06-07 | 1998-11-17 | Cytotherapeutics, Inc. | Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane |
| US5869270A (en) * | 1996-01-31 | 1999-02-09 | Sunol Molecular Corporation | Single chain MHC complexes and uses thereof |
| EP0995798A1 (en) * | 1998-10-24 | 2000-04-26 | Novimmune Sa | Transcription factor of MHC class II genes, substances capable of inhibiting this new transcription factor and medical uses of these substances |
| US20040225112A1 (en) | 2003-05-06 | 2004-11-11 | Crew Mark D. | Genes encoding single chain human leukocyte antigen E (HLA-E) proteins to prevent natural killer cell-mediated cytotoxicity |
| WO2007091078A2 (en) | 2006-02-10 | 2007-08-16 | Axordia Limited | Polypeptide conjugate comprising hla-g and uses thereof, stem cells transfected with hla-g |
| US8105831B2 (en) | 2007-03-09 | 2012-01-31 | University Of Washington | Parvoviral production of HLA homozygous cells |
| AU2011281062B2 (en) * | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| CA3205636A1 (en) * | 2011-04-20 | 2012-10-26 | University Of Washington Through Its Center For Commercialization | Beta-2 microglobulin-deficient cells |
-
2013
- 2013-03-15 FI FIEP13714128.9T patent/FI2838548T3/fi active
- 2013-03-15 ES ES13714128T patent/ES2959382T3/es active Active
- 2013-03-15 EP EP23173587.9A patent/EP4253409A3/en active Pending
- 2013-03-15 HU HUE13714128A patent/HUE063231T2/hu unknown
- 2013-03-15 PL PL13714128.9T patent/PL2838548T3/pl unknown
- 2013-03-15 US US14/391,328 patent/US20150056225A1/en not_active Abandoned
- 2013-03-15 JP JP2015507006A patent/JP2015514421A/ja active Pending
- 2013-03-15 PT PT137141289T patent/PT2838548T/pt unknown
- 2013-03-15 DK DK13714128.9T patent/DK2838548T5/da active
- 2013-03-15 CA CA2870571A patent/CA2870571C/en active Active
- 2013-03-15 WO PCT/US2013/032058 patent/WO2013158292A1/en not_active Ceased
- 2013-03-15 EP EP13714128.9A patent/EP2838548B1/en active Active
- 2013-03-15 CA CA3085032A patent/CA3085032A1/en active Pending
- 2013-03-15 AU AU2013249820A patent/AU2013249820C1/en active Active
-
2019
- 2019-02-06 JP JP2019019289A patent/JP7130571B2/ja active Active
- 2019-06-14 US US16/441,889 patent/US20190365876A1/en active Pending
-
2022
- 2022-08-24 JP JP2022132891A patent/JP7531925B2/ja active Active
-
2024
- 2024-07-24 JP JP2024118377A patent/JP2024144548A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514421A5 (https=) | ||
| Heijmans et al. | Comparative genetics of the major histocompatibility complex in humans and nonhuman primates | |
| Behl et al. | The major histocompatibility complex in bovines: a review | |
| Grant et al. | The unconventional role of HLA-E: The road less traveled | |
| Norman et al. | Sequences of 95 human MHC haplotypes reveal extreme coding variation in genes other than highly polymorphic HLA class I and II | |
| Bontrop | Comparative genetics of MHC polymorphisms in different primate species: duplications and deletions | |
| Tomita et al. | BCG vaccine may generate cross-reactive T cells against SARS-CoV-2: In silico analyses and a hypothesis | |
| JP2022162047A5 (https=) | ||
| Klein et al. | MHC polymorphism and parasites | |
| Donaldson et al. | The molecular genetics of autoimmune liver disease | |
| Long et al. | Stress signals activate natural killer cells | |
| Goldberg et al. | MHC structure and function–antigen presentation. Part 1 | |
| Augusto et al. | KIR and HLA under pressure: evidences of coevolution across worldwide populations | |
| Price et al. | Heritable factors distinguish two types of alopecia areata | |
| Castelli et al. | HLA-E coding and 3′ untranslated region variability determined by next-generation sequencing in two West-African population samples | |
| JP2012516140A5 (https=) | ||
| Codner et al. | Constraints on haplotype structure and variable gene frequencies suggest a functional hierarchy within cattle MHC class I | |
| Bimber et al. | The killer‐cell immunoglobulin‐like receptors of macaques | |
| Ellis | The cattle major histocompatibility complex: is it unique? | |
| Baccala et al. | Mycoplasma arthritidis mitogen. Vβ engaged in mice, rats, and humans, and requirement of HLA‐DRα for presentation | |
| Augusto et al. | A deep look at KIR–HLA in Amerindians: comprehensive meta-analysis reveals limited diversity of KIR haplotypes | |
| Ewald et al. | Distinctive polymorphism of chicken B-FI (major histocompatibility complex class I) molecules | |
| de Groot et al. | Unraveling the architecture of major histocompatibility complex class II haplotypes in rhesus macaques | |
| Schwartz et al. | The assembly and characterisation of two structurally distinct cattle MHC class I haplotypes point to the mechanisms driving diversity | |
| de Groot et al. | The chimpanzee Mhc-DRB region revisited: gene content, polymorphism, pseudogenes, and transcripts |